Evidence
Cell Mol Life Sci. 2024 Apr 23;81(1):192. doi: 10.1007/s00018-024-05225-z.
ABSTRACT
BACKGROUND: Alzheimer’s disease (AD) is pathologically characterized by the abnormal accumulation of Aβ and tau proteins. There has long been a keen interest among researchers in understanding how Aβ and tau are ultimately cleared in the brain. The discovery of this glymphatic system introduced a novel perspective on protein clearance and it gained recognition as one of the major brain clearance pathways for clearing these pathogenic proteins in AD. This finding has sparked interest in exploring the potential contribution of the glymphatic/meningeal lymphatic system in AD. Furthermore, there is a growing emphasis and discussion regarding the possibility that activating the glymphatic/meningeal lymphatic system could serve as a novel therapeutic strategy against AD.
OBJECTIVES: Given this current research trend, the primary focus of this comprehensive review is to highlight the role of the glymphatic/meningeal lymphatic system in the pathogenesis of AD. The discussion will encompass future research directions and prospects for treatment in relation to the glymphatic/meningeal lymphatic system.
PMID:38652179 | DOI:10.1007/s00018-024-05225-z
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Involvement of the glymphatic/meningeal lymphatic system in Alzheimer’s disease: insights into proteostasis and future directions
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- Impaired Meningeal Lymphatics and Glymphatic Pathway in Patients with White Matter Hyperintensity
- Chronic sleep fragmentation impairs brain interstitial clearance in young wildtype mice
- Human brain clearance imaging: Pathways taken by magnetic resonance imaging contrast agents after administration in cerebrospinal fluid and blood
- Brain vasculature accumulates tau and is spatially related to tau tangle pathology in Alzheimer's disease
- Tau fibrils evade autophagy by excessive p62 coating and TAX1BP1 exclusion
- CSF formation rate-a potential glymphatic flow parameter in hydrocephalus?
- Tau follows principal axes of functional and structural brain organization in Alzheimer's disease
- Liver as a new target organ in Alzheimer's disease: insight from cholesterol metabolism and its role in amyloid-beta clearance
- Tau propagation in the brain olfactory circuits is associated with smell perception changes in aging
- Resting-state fMRI network efficiency as a mediator in the relationship between the glymphatic system and cognitive function in obstructive sleep apnea hypopnea syndrome: Insights from a DTI-ALPS investigation
- Functional myelin in cognition and neurodevelopmental disorders
- The complexity of extracellular vesicles: Bridging the gap between cellular communication and neuropathology
- Behavioral and Metabolic Effects of ABCG4 KO in the APPswe,Ind (J9) Mouse Model of Alzheimer's Disease
- S100 proteins: a new frontier in fibromyalgia research
- Generation and characterization of cerebellar granule neurons specific knockout mice of Golli-MBP
- Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease
- Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease
- Early and selective localization of tau filaments to glutamatergic subcellular domains within the human anterodorsal thalamus
- Hypoglycemia and Alzheimer Disease Risk: The Possible Role of Dasiglucagon
- Mark4 ablation attenuates pathological phenotypes in a mouse model of tauopathy
- Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry
- Reduction of spermine synthase enhances autophagy to suppress Tau accumulation
- The influence of APOEε4 on the pTau interactome in sporadic Alzheimer's disease
- Differential Cytokine Responses of APOE3 and APOE4 Blood-brain Barrier Cell Types to SARS-CoV-2 Spike Proteins
- Blood biomarkers open a window to brain pathophysiology in Alzheimer's disease
- Multiple system atrophy with amyloid-b-predominant Alzheimer's disease neuropathologic change
- Tau- and α-synuclein-targeted gold nanoparticles: applications, opportunities, and future outlooks in the diagnosis and therapy of neurodegenerative diseases
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- Neuroimmune Dysfunction in Alzheimer's Disease and Other Forms of Dementia
- Towards cascading genetic risk in Alzheimer's disease
- A clathrin mediated endocytosis scaffolding protein, Intersectin 1, changes in an isoform, brain region, and sex specific manner in Alzheimer's disease
- Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease
- Genomic stress and impaired DNA repair in Alzheimer disease
- D-peptide-magnetic nanoparticles fragment tau fibrils and rescue behavioral deficits in a mouse model of Alzheimer's disease
- Apolipoprotein E2 Expression Alters Endosomal Pathways in a Mouse Model With Increased Brain Exosome Levels During Aging
- Bacteroidota inhibit microglia clearance of amyloid-beta and promote plaque deposition in Alzheimer's disease mouse models
- G272V and P301L mutations induce isoform specific tau mislocalization to dendritic spines and synaptic dysfunctions in cellular models of 3R and 4R tau frontotemporal dementia
- Impaired Glymphatic Flow on Diffusion Tensor MRI as a Marker of Neurodegeneration in Alzheimer's Disease: Correlation with Gray Matter Volume Loss and Cognitive Decline Independent of Cerebral Amyloid Deposition
- Impaired Glymphatic Flow on Diffusion Tensor MRI as a Marker of Neurodegeneration in Alzheimer's Disease: Correlation with Gray Matter Volume Loss and Cognitive Decline Independent of Cerebral Amyloid Deposition
- Research progress on astrocyte-derived extracellular vesicles in the pathogenesis and treatment of neurodegenerative diseases
- Evaluation of the Glymphatic System in Schizophrenia Spectrum Disorder Using Proton Magnetic Resonance Spectroscopy Measurement of Brain Macromolecule and Diffusion Tensor Image Analysis Along the Perivascular Space Index
- Evaluation of the Glymphatic System in Schizophrenia Spectrum Disorder Using Proton Magnetic Resonance Spectroscopy Measurement of Brain Macromolecule and Diffusion Tensor Image Analysis Along the Perivascular Space Index
- Cholecystokinin neurotransmission in the central nervous system: Insights into its role in health and disease
- A new tau dephosphorylation-targeting chimera for the treatment of tauopathies
- Evidence for a novel neuronal mechanism driving Alzheimer's disease, upstream of amyloid
- Distinct ultrastructural phenotypes of glial and neuronal alpha-synuclein inclusions in multiple system atrophy
- In situ seeding assay: A novel technique for direct tissue localization of bioactive tau
- The vascular contribution of apolipoprotein E to Alzheimer's disease
- Ubiquitin system mutations in neurological diseases
- Cannabidiol and Neurodegeneration: From Molecular Mechanisms to Clinical Benefits
- Cannabidiol and Neurodegeneration: From Molecular Mechanisms to Clinical Benefits
- Alzheimer-Type Cerebral Amyloidosis in the Context of HIV Infection: Implications for a Proposed New Treatment Approach
- G-protein coupled estrogen receptor 1, amyloid-β, and tau tangles in older adults
- How can we manage progressive supranuclear palsy syndrome with pharmacotherapy?
- Overexpression of pathogenic tau in astrocytes causes a reduction in AQP4 and GLT1, an immunosuppressed phenotype and unique transcriptional responses to repetitive mild TBI without appreciable changes in tauopathy
- Disease-Modifying Treatments and Their Future in Alzheimer's Disease Management
- Phytoactive drugs used in the treatment of Alzheimer's disease and dementia
- The disease-causing tau V337M mutation induces tau hypophosphorylation and perturbs axon morphology pathways
- Prenatal treatment with preimplantation factor improves early postnatal neurogenesis and cognitive impairments in a mouse model of Down syndrome
- Potassium and calcium channels in different nerve cells act as therapeutic targets in neurological disorders
- Small but mighty: the rise of microprotein biology in neuroscience
- Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles
- Role of PIM Kinase Inhibitor in the Treatment of Alzheimer's Disease
- The Role of Vitamin K in the Development of Neurodegenerative Diseases
Evidence Blueprint
Involvement of the glymphatic/meningeal lymphatic system in Alzheimer’s disease: insights into proteostasis and future directions
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Involvement of the glymphatic/meningeal lymphatic system in Alzheimer’s disease: insights into proteostasis and future directions
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Interplay between the glymphatic system and neurotoxic proteins in Parkinson's disease and related disorders: current knowledge and future directions
- Mechanisms behind changes of neurodegeneration biomarkers in plasma induced by sleep deprivation
- Deregulation of the Glymphatic System in Alzheimer's Disease: Genetic and Non-Genetic Factors
- Unraveling the lymphatic system in the spinal cord meninges: a critical element in protecting the central nervous system
- Mistranslation-associated perturbations of proteostasis do not promote accumulation of amyloid beta and plaque deposition in aged mouse brain
- Impaired Meningeal Lymphatics and Glymphatic Pathway in Patients with White Matter Hyperintensity
- Chronic sleep fragmentation impairs brain interstitial clearance in young wildtype mice
- Human brain clearance imaging: Pathways taken by magnetic resonance imaging contrast agents after administration in cerebrospinal fluid and blood
- Global brain activity and its coupling with cerebrospinal fluid flow is related to tau pathology
- Brain vasculature accumulates tau and is spatially related to tau tangle pathology in Alzheimer's disease
- Reduced Diffusivity Along Perivascular Spaces on Magnetic Resonance Imaging Associated with Younger Age of First Use and Cognitive Impairment in Recreational Marijuana Users
- Glymphatic dysfunction in patients with early-stage amyotrophic lateral sclerosis
- p-tau Ser356 is associated with Alzheimer's disease pathology and is lowered in brain slice cultures using the NUAK inhibitor WZ4003
- BV2 Membrane-coated PEGylated-liposomes Delivered hFGF21 to Cortical and Hippocampal Microglia for Alzheimer's Disease Therapy
- Ischemia-Reperfusion Programming of Alzheimer's Disease-Related Genes-A New Perspective on Brain Neurodegeneration after Cardiac Arrest
- Tau fibrils evade autophagy by excessive p62 coating and TAX1BP1 exclusion
- Unraveling the impact of Omega-3 polyunsaturated fatty acids on blood-brain barrier (BBB) integrity and glymphatic function
- Imaging of brain barrier inflammation and brain fluid drainage in human neurological diseases
- Evaluation of glymphatic system activity using diffusion tensor image analysis along the perivascular space and amyloid PET in older adults with objectively normal cognition: a preliminary study
- Quantifying the Lymphatic Transport of Model Therapeutics from the Brain in Rats
- Neonatal stress disrupts the glymphatic system development and increases the susceptibility to Parkinson's disease in later life
- Role of Oxidative Stress, Methionine Oxidation and Methionine Sulfoxide Reductases (MSR) in Alzheimer's Disease
- Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease
- CSF formation rate-a potential glymphatic flow parameter in hydrocephalus?
- Tau follows principal axes of functional and structural brain organization in Alzheimer's disease
- Autophagy and exosomes; inter-connected maestros in Alzheimer's disease
- Tau accumulation and its spatial progression across the Alzheimer's disease spectrum
- New insights into the therapeutic approaches for the treatment of tauopathies
- Disease and brain region specific immune response profiles in neurodegenerative diseases with pure and mixed protein pathologies
- Traumatic Brain Injury in Mice Generates Early-Stage Alzheimer's Disease Related Protein Pathology that Correlates with Neurobehavioral Deficits
- Chronic kidney disease causes blood-brain barrier breakdown via urea-activated matrix metalloproteinase-2 and insolubility of tau protein
- Biochemical approaches to assess the impact of post-translational modifications on pathogenic tau conformations using recombinant protein
- Navigating the metabolic maze: anomalies in fatty acid and cholesterol processes in Alzheimer's astrocytes
- CSF protein ratios with enhanced potential to reflect Alzheimer's disease pathology and neurodegeneration
- Liver as a new target organ in Alzheimer's disease: insight from cholesterol metabolism and its role in amyloid-beta clearance
- Mutant α-synuclein propagates via the lymphatic system of the brain in the monomeric state
- Vascular risk factors and astrocytic marker for the glymphatic system activity
- Tau propagation in the brain olfactory circuits is associated with smell perception changes in aging
- Proteomic analysis of P. gingivalis-Lipopolysaccharide induced neuroinflammation in SH-SY5Y and HMC3 cells
- Molecular cross-talk between long COVID-19 and Alzheimer's disease
- Primary Hypothyroidism and Alzheimer's Disease: A Tale of Two
- Localized proteomic differences in the choroid plexus of Alzheimer's disease and epilepsy patients
- Resting-state fMRI network efficiency as a mediator in the relationship between the glymphatic system and cognitive function in obstructive sleep apnea hypopnea syndrome: Insights from a DTI-ALPS investigation
- Spatial transcriptomic patterns underlying amyloid-β and tau pathology are associated with cognitive dysfunction in Alzheimer's disease
- Exposure to low-intensity blast increases clearance of brain Aβ
- Functional myelin in cognition and neurodevelopmental disorders
- The complexity of extracellular vesicles: Bridging the gap between cellular communication and neuropathology
- Cryptic splicing of stathmin-2 and UNC13A mRNAs is a pathological hallmark of TDP-43-associated Alzheimer's disease
- Detection, visualization and quantification of protein complexes in human Alzheimer's disease brains using proximity ligation assay
- Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease
- Impact of Sleep Disorders and Disturbed Sleep on Brain Health: A Scientific Statement From the American Heart Association
- Targeted examination of amyloid beta and tau protein accumulation via positron emission tomography for the differential diagnosis of Alzheimer's disease based on the A/T(N) research framework
- Behavioral and Metabolic Effects of ABCG4 KO in the APPswe,Ind (J9) Mouse Model of Alzheimer's Disease
- S100 proteins: a new frontier in fibromyalgia research
- Generation and characterization of cerebellar granule neurons specific knockout mice of Golli-MBP
- Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease
- Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease
- Early and selective localization of tau filaments to glutamatergic subcellular domains within the human anterodorsal thalamus
- Hypoglycemia and Alzheimer Disease Risk: The Possible Role of Dasiglucagon
- The proteomic effects of ketone bodies: implications for proteostasis and brain proteinopathies
- Mark4 ablation attenuates pathological phenotypes in a mouse model of tauopathy
- Tau and Alzheimer's disease: Past, present and future
- Advancements in investigating the role of cerebral small vein loss in Alzheimer's disease-related pathological changes
- Shaping the future of preclinical development of successful disease-modifying drugs against Alzheimer's disease: a systematic review of tau propagation models